Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04433546 · ClinicalTrials.gov registry record · Phase 2
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
A Phase 2 study, sponsored by PhaseBio Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04433546 is a Phase 2 study that was terminated before completion, run by PhaseBio Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT04433546, a Phase 2 study, was terminated before completion, sponsored by PhaseBio Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Interventions
- DRUG Pemziviptadil (PB1046)
- DRUG Low Dose (10 mg) Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2020-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04433546
The ClinicalTrials.gov registry entry for NCT04433546 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PhaseBio Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemziviptadil (PB1046) is the first listed.
NCT04433546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04433546 about?
NCT04433546 is a clinical study titled "Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).". This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The s...
What is the current status of trial NCT04433546?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-07-15. Estimated completion is 2020-12-02.
What interventions are being tested in trial NCT04433546?
The interventions under investigation include: Pemziviptadil (PB1046) (DRUG), Low Dose (10 mg) Control (DRUG).
Who is sponsoring clinical trial NCT04433546?
This trial is sponsored by PhaseBio Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.